AMD/RETINA

Most patients starting brolucizumab switch from prior anti-VEGF therapy

Approximately 94% of patients initiating treatment with brolucizumab for wet AMD switched from a different anti-VEGF treatment, according to data presented at AAO 2020 Virtual. Using patients with wet AMD included in the IRIS Registry, researchers analyzed patient characteristics and early outcomes from 10,594 eyes (9547 patients) that had received...